XML 63 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
Unaudited Quarterly Results (unaudited)
 12 Months Ended
Dec. 31, 2013
Unaudited Quarterly Results (unaudited) [Abstract]  
Unaudited Quarterly Results (unaudited)
15. Unaudited Quarterly Results (unaudited)

Summarized quarterly financial data during 2013 and 2012 are as follows:

 
 
2013 Quarter Ended
 
 
 
March 31
  
June 30
  
September 30
  
December 31
 
Revenues
 
$
2,226
  
$
1,801
  
$
867
  
$
2,968
 
Net loss
  
(11,258
)
  
(12,263
)
  
(10,500
)
  
(8,551
)
Net loss per share - basic and diluted
  
(0.22
)
  
(0.24
)
  
(0.17
)
  
(0.14
)

 
 
2012 Quarter Ended
 
 
 
March 31
  
June 30
  
September 30
  
December 31
 
Revenues (1)
 
$
2,226
  
$
1,820
  
$
1,117
  
$
8,885
 
Net loss
  
(13,086
)
  
(10,720
)
  
(11,301
)
  
(324
)
Net loss per share - basic and diluted
  
(0.39
)
  
(0.32
)
  
(0.33
)
  
(0.01
)
_______________

(1)
Revenues in the fourth quarter of 2012 include $5.0 million and $2.8 million from the MedImmune and CytoDyn Agreements, respectively.